Last reviewed · How we verify
Catapres-TTS-1
Catapres-TTS-1, marketed by Boehringer Ingelheim, is a well-established treatment in its class with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing market presence and established efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Catapres-TTS-1 |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (PHASE2)
- AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures (EARLY_PHASE1)
- Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients (PHASE1)
- Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial) (PHASE3)
- The PREVENT AGITATION Trial II - Children ≤1 Year (PHASE2, PHASE3)
- A Study of Colesevelam in Fecal Incontinence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Catapres-TTS-1 CI brief — competitive landscape report
- Catapres-TTS-1 updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI